Pioglitazone and Rosiglitazone Decrease Prostaglandin E2 in Non–Small-Cell Lung Cancer Cells by Up-Regulating 15-Hydroxyprostaglandin Dehydrogenase
- 1 June 2007
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 71 (6) , 1715-1720
- https://doi.org/10.1124/mol.106.033357
Abstract
Lung cancer cells elaborate the immunosuppressive and antiapoptotic mediator prostaglandin E2 (PGE2), a product of cyclooxygenase-2 (COX-2) enzyme activity. Because peroxisome proliferator-activated receptor (PPAR)γ ligands, such as thiazolidinediones (TZDs), inhibit lung cancer cell growth, we examined the effect of the TZDs pioglitazone and rosiglitazone on PGE2 levels in non–small-cell lung cancer (NSCLC) A427 and A549 cells. Both TZDs inhibited PGE2 production in NSCLC cells via a COX-2 independent pathway. To define the mechanism underlying COX-2 independent suppression of PGE2 production, we focused on other enzymes responsible for the synthesis and degradation of PGE2. The expression of none of the three prostaglandin synthases (microsomal PGES1, PGES2 and cystosolic PGES) was down-regulated by the TZDs. It is noteworthy that 15-hydroxyprostaglandin dehydrogenase (15-PGDH), an enzyme that produces biologically inactive 15-ketoprostaglandins from active PGE2, was induced by TZDs. The TZD-mediated suppression of PGE2 concentration was significantly inhibited by small interfering RNA to 15-PGDH. Studies using dominant-negative PPARγ overexpression or 2-chloro-5-nitrobenzanilide (GW9662; a PPARγ antagonist) revealed that the suppressive effect of the TZDs on PGE2 is PPARγ-independent. Together, these findings indicate that it is possible to use a clinically available pharmacological intervention to suppress tumor-derived PGE2 by enhancing catabolism rather than blocking synthesis.This publication has 29 references indexed in Scilit:
- Thiazolidinediones and inflammationLupus, 2005
- PPAR-γ Activation Inhibits Angiogenesis by Blocking ELR+CXC Chemokine Production in Non-small Cell Lung CancerNeoplasia, 2005
- 15-Hydroxyprostaglandin Dehydrogenase Is Down-regulated in Colorectal CancerJournal of Biological Chemistry, 2005
- Pulmonary Prostacyclin Synthase Overexpression Chemoprevents Tobacco Smoke Lung Carcinogenesis in MiceCancer Research, 2004
- NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancerCarcinogenesis: Integrative Cancer Research, 2004
- Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistanceDiabetes, Obesity and Metabolism, 2004
- Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancerOncogene, 2004
- Inhibition of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agentsProstaglandins, Leukotrienes & Essential Fatty Acids, 2002
- PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammationNature Medicine, 2001
- A Dominant-negative Peroxisome Proliferator-activated Receptor γ (PPARγ) Mutant Is a Constitutive Repressor and Inhibits PPARγ-mediated AdipogenesisJournal of Biological Chemistry, 2000